Contact
searchSearch
HMP Global
Login

Abuse, PTSD, & Trauma Topic Center

Bruce Fischer
Q&As
Family of Origin Psychotherapy in Addiction Treatment Creates ‘Beneficial Change,’ Expert Says
09/07/2024
Bruce Fischer, PhD, LP, LMFT, a member of the Cape Cod Symposium 2024 (CCS) faculty, discusses the use of family genograms and motivational interviewing to identify and address intergenerational trauma and addiction within a family system.
Bruce Fischer, PhD, LP, LMFT, a member of the Cape Cod Symposium 2024 (CCS) faculty, discusses the use of family genograms and motivational interviewing to identify and address intergenerational trauma and addiction within a family system.
Bruce Fischer, PhD, LP, LMFT, a...
09/07/2024
Psychiatry & Behavioral Health
From Psychiatry & Behavioral Health
fda building sign
News
FDA Rejection of MDMA-Assisted Therapy for PTSD Divides Psychedelic Stakeholders
08/16/2024
The US Food and Drug Administration (FDA) last week rejected the new drug application (NDA) from Lykos Therapeutics for midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD) in conjunction with...
The US Food and Drug Administration (FDA) last week rejected the new drug application (NDA) from Lykos Therapeutics for midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD) in conjunction with...
The US Food and Drug...
08/16/2024
Psych Congress Network
FDA Considers Supplemental NDA for Brexpiprazole Plus Sertraline for PTSD
News
FDA Considers Supplemental NDA for Brexpiprazole Plus Sertraline for PTSD
07/24/2024
The US Food and Drug Administration recently accepted a supplemental New Drug Application for brexpiprazole in combination with sertraline for the treatment of adults with PTSD, announced codevelopers Otsuka Pharmaceutical Co. Ltd. and H....
The US Food and Drug Administration recently accepted a supplemental New Drug Application for brexpiprazole in combination with sertraline for the treatment of adults with PTSD, announced codevelopers Otsuka Pharmaceutical Co. Ltd. and H....
The US Food and Drug...
07/24/2024
Psych Congress Network
Grief-Related Psychiatric Conditions Common Among Bereaved Adults
News
Grief-Related Psychiatric Conditions Common Among Bereaved Adults
07/16/2024
PTSD, MDD, and PGD appear highly prevalent and comorbid among bereaved US adults, particularly those who experienced a traumatic loss of a psychologically close other.
PTSD, MDD, and PGD appear highly prevalent and comorbid among bereaved US adults, particularly those who experienced a traumatic loss of a psychologically close other.
PTSD, MDD, and PGD appear highly...
07/16/2024
Psych Congress Network
andrew penn
Videos
Decoding the FDA Committee's Decision to Reject MDMA-Assisted Therapy: Part 2
07/01/2024
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP,...
07/01/2024
Psych Congress Network
andrew penn
Videos
Decoding the FDA Committee's Decision to Reject MDMA-Assisted Therapy With Andrew Penn, MS, PMHNP
06/21/2024
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP,...
06/21/2024
Psych Congress Network
FDA
News
FDA Advisory Committee Rejects First MDMA Treatment for PTSD
06/06/2024
FDA committee rejected an MDMA-based therapy for adult PTSD treatment due to concerns about its effectiveness and the reliability of the data, despite positive study results.
FDA committee rejected an MDMA-based therapy for adult PTSD treatment due to concerns about its effectiveness and the reliability of the data, despite positive study results.
FDA committee rejected an...
06/06/2024
Psych Congress Network
Traumatic Events May Affect Psychiatric Disorder Development, Moreso Than Familial Factors
News
Traumatic Events May Affect Psychiatric Disorder Development, Moreso Than Familial Factors
01/23/2024
Assault, bereavement, and injury were significantly associated with an increased risk of subsequent psychiatric disorders, independent of familial background, in a nationwide cohort study recently published in JAMA Psychiatry. 
Assault, bereavement, and injury were significantly associated with an increased risk of subsequent psychiatric disorders, independent of familial background, in a nationwide cohort study recently published in JAMA Psychiatry. 
Assault, bereavement, and injury...
01/23/2024
Psych Congress Network
News
CPT III Codes for Psychedelic-Assisted Therapies Take Effect
01/05/2024
The temporary codes, which went into effect this week, allow providers to seek coverage and reimbursement for delivery of psychedelic-assisted therapies, pending their approval by the FDA.
The temporary codes, which went into effect this week, allow providers to seek coverage and reimbursement for delivery of psychedelic-assisted therapies, pending their approval by the FDA.
The temporary codes, which went...
01/05/2024
Psych Congress Network
News
MAPS PBC Submits New Drug Application for MDMA-Assisted Therapy for PTSD
12/12/2023
MAPS Public Benefit Corporation’s new drug application to the US Food and Drug Administration for the use of MDMA in combination with psychotherapy to treat post-traumatic stress disorder is the first filing to the FDA for any...
MAPS Public Benefit Corporation’s new drug application to the US Food and Drug Administration for the use of MDMA in combination with psychotherapy to treat post-traumatic stress disorder is the first filing to the FDA for any...
MAPS Public Benefit...
12/12/2023
Psych Congress Network
Andrew Penn, RN, PMHNP, and Charles Raison, MD
News
Studies Illustrate Potential of MDMA-, Psilocybin-Assisted Therapies
10/30/2023
Andrew Penn, RN, PMHNP, and Charles Raison, MD, shared findings from late-stage trials for MDMA-assisted therapy to treat post-traumatic stress disorder and the use of psilocybin for treatment-resistant depression and major depressive...
Andrew Penn, RN, PMHNP, and Charles Raison, MD, shared findings from late-stage trials for MDMA-assisted therapy to treat post-traumatic stress disorder and the use of psilocybin for treatment-resistant depression and major depressive...
Andrew Penn, RN, PMHNP, and...
10/30/2023
Psych Congress Network

Perspectives

Bruce Fischer
Q&As
Family of Origin Psychotherapy in Addiction Treatment Creates ‘Beneficial Change,’ Expert Says
09/07/2024
Bruce Fischer, PhD, LP, LMFT, a member of the Cape Cod Symposium 2024 (CCS) faculty, discusses the use of family genograms and motivational interviewing to identify and address intergenerational trauma and addiction within a family system.
Bruce Fischer, PhD, LP, LMFT, a member of the Cape Cod Symposium 2024 (CCS) faculty, discusses the use of family genograms and motivational interviewing to identify and address intergenerational trauma and addiction within a family system.
Bruce Fischer, PhD, LP, LMFT, a...
09/07/2024
Psychiatry & Behavioral Health
Lydia Anne Bartholow
Q&As
Utilizing Trauma-Informed Approaches for Collaborative and Empowering Care
06/02/2023
The latest coverage from Psych Congress Elevate 2023 in Las Vegas, Nevada.
The latest coverage from Psych Congress Elevate 2023 in Las Vegas, Nevada.
The latest coverage from Psych...
06/02/2023
Psych Congress Network
Alana Iglewicz, MD
Q&As
Prioritizing Practical Care When Treating Prologued Grief Disorder
09/17/2022
Over 2 years after the onset of COVID-19, few lives remain untouched by the public health crisis.
Over 2 years after the onset of COVID-19, few lives remain untouched by the public health crisis.
Over 2 years after the onset of...
09/17/2022
Psych Congress Network
Cyrus and Ross
Q&A
Understanding Sociological and Neurobiological Theories Related to Trauma
12/08/2021
In this Q&A, Kali Cyrus, MD, MPH, and Rachel Ross, MD, PhD, elaborate on their Psych Congress 2021 session, “Rethinking Approaches to Trauma for the 21st Century: Underlying Neurobiology and Practical Applications to Big “T” and Little “t”...
In this Q&A, Kali Cyrus, MD, MPH, and Rachel Ross, MD, PhD, elaborate on their Psych Congress 2021 session, “Rethinking Approaches to Trauma for the 21st Century: Underlying Neurobiology and Practical Applications to Big “T” and Little “t”...
In this Q&A, Kali Cyrus, MD,...
12/08/2021
Psych Congress Network
Blog
Preparing for COVID-19-Induced PTSD Among Health Care Providers
04/28/2020
BLOG: Now is the time for us as mental health care providers to begin to prepare ways to reach out to our colleagues on the frontlines to make our services more easily available, starting with the assumption that they are traumatized until...
BLOG: Now is the time for us as mental health care providers to begin to prepare ways to reach out to our colleagues on the frontlines to make our services more easily available, starting with the assumption that they are traumatized until...
BLOG: Now is the time for us as...
04/28/2020
Psych Congress Network
Q&A
Understanding the Damaging Effects of Trauma
02/20/2020
Psychiatrist Sarah Vinson, MD, associate clinical professor of psychiatry and pediatrics at Morehouse School of Medicine, Atlanta, Georgia, will coach attendees on trauma diagnosis and treatment at the upcoming Elevate by Psych Congress...
Psychiatrist Sarah Vinson, MD, associate clinical professor of psychiatry and pediatrics at Morehouse School of Medicine, Atlanta, Georgia, will coach attendees on trauma diagnosis and treatment at the upcoming Elevate by Psych Congress...
Psychiatrist Sarah Vinson, MD,...
02/20/2020
Psych Congress Network
Blog
Watch for our nation`s post-traumatic reactions
09/18/2017
Our nation has been in the eye of two hurricanes—literally and figuratively—punctuated by the exclamation point of the 16th anniversary of 9/11. One way or another, nearly everybody has been affected emotionally.
Our nation has been in the eye of two hurricanes—literally and figuratively—punctuated by the exclamation point of the 16th anniversary of 9/11. One way or another, nearly everybody has been affected emotionally.
Our nation has been in the eye...
09/18/2017
Psych Congress Network
Blog
Vicarious Traumatization in Psychiatrists
10/08/2015
A recent study of medical students found that 26% of students reported symptoms of vicarious traumatization in their third year of medical school and of these, 50% identified their psychiatry clerkship as the source.
A recent study of medical students found that 26% of students reported symptoms of vicarious traumatization in their third year of medical school and of these, 50% identified their psychiatry clerkship as the source.
A recent study of medical...
10/08/2015
Psych Congress Network
Blog
PTSD in Physicians
09/16/2015
Dr. Myers shares highlights of his presentation titled “PTSD in Psychiatrists: A Hidden Epidemic.”
Dr. Myers shares highlights of his presentation titled “PTSD in Psychiatrists: A Hidden Epidemic.”
Dr. Myers shares highlights of...
09/16/2015
Psych Congress Network
Blog
Where forgiveness fits in the Charleston tragedy
06/22/2015
There are so many important mental health aspects to discuss within the tragic event at the Charleston Church in South Carolina. Among them are:
There are so many important mental health aspects to discuss within the tragic event at the Charleston Church in South Carolina. Among them are:
There are so many important...
06/22/2015
Psych Congress Network
Thomas L. Schwartz, MD
Q&As
How Psychiatrists Can Address Sleep-Wake Disorders Effectively
11/09/2024
Thomas L. Schwartz, MD, shares exclusive insights from his session on sleep-wake issues presented at the 2024 NEI Fall Congress.
Thomas L. Schwartz, MD, shares exclusive insights from his session on sleep-wake issues presented at the 2024 NEI Fall Congress.
Thomas L. Schwartz, MD, shares...
11/09/2024
Psychiatry & Behavioral Health
Michelle Martel, PhD
Q&As
When It Comes to ADHD in Women, There's Still So Much to Learn
10/31/2024
Michelle Martel, PhD, shares insights from her session on ADHD in women presented at the 2024 Psych Congress.
Michelle Martel, PhD, shares insights from her session on ADHD in women presented at the 2024 Psych Congress.
Michelle Martel, PhD, shares...
10/31/2024
Psych Congress Network
Andrew Penn
Q&As
Psychedelics: New Research, Regulations, and Horizons
10/30/2024
"Psychedelic therapies must continue to be researched so that perhaps, someday with their help, we will be able to help our patients live their best lives," Andrew Penn, PMHNP-BC.
"Psychedelic therapies must continue to be researched so that perhaps, someday with their help, we will be able to help our patients live their best lives," Andrew Penn, PMHNP-BC.
"Psychedelic therapies must...
10/30/2024
Psych Congress Network
Jo Hughes
Q&As
Unpacking the Pressing Challenges of Polypharmacy in Psychiatry
10/30/2024
Jo Hughes, DMSc, PA-C, CAQ-PSY, discusses the complexities of polypharmacy in psychiatry and the balance between medication management and patient safety.
Jo Hughes, DMSc, PA-C, CAQ-PSY, discusses the complexities of polypharmacy in psychiatry and the balance between medication management and patient safety.
Jo Hughes, DMSc, PA-C, CAQ-PSY,...
10/30/2024
Psych Congress Network
Beau Kilmer, PhD
Q&As
Psychedelic Policy and Market Considerations
10/28/2024
Dr Kilmer discusses the psychedelic market in the United States, policy on both state and local levels, and the role of the federal government in regulation.
Dr Kilmer discusses the psychedelic market in the United States, policy on both state and local levels, and the role of the federal government in regulation.
Dr Kilmer discusses the...
10/28/2024
Psych Congress Network
Dr Chepke
Q&As
How should clinicians choose one lithium formulation over another?
09/09/2024
Join Craig Chepke, MD, DFAPA, medical director of Excel Psychiatric Associates, as he demystifies the complexities of lithium formulations.
Join Craig Chepke, MD, DFAPA, medical director of Excel Psychiatric Associates, as he demystifies the complexities of lithium formulations.
Join Craig Chepke, MD, DFAPA,...
09/09/2024
Psych Congress Network
Mark Garofoli
Q&As
A Closer Look at the Updated CDC Opioid Guideline
09/08/2024
Dr Garofoli discusses the key changes in the CDC's 2022 Opioid Guideline Update and their impact on clinical practice, highlights the expanded scope of the guidelines to all outpatient settings, the nuanced approach to pain management, and...
Dr Garofoli discusses the key changes in the CDC's 2022 Opioid Guideline Update and their impact on clinical practice, highlights the expanded scope of the guidelines to all outpatient settings, the nuanced approach to pain management, and...
Dr Garofoli discusses the key...
09/08/2024
Psychiatry & Behavioral Health
Bruce Fischer
Q&As
Family of Origin Psychotherapy in Addiction Treatment Creates ‘Beneficial Change,’ Expert Says
09/07/2024
Bruce Fischer, PhD, LP, LMFT, a member of the Cape Cod Symposium 2024 (CCS) faculty, discusses the use of family genograms and motivational interviewing to identify and address intergenerational trauma and addiction within a family system.
Bruce Fischer, PhD, LP, LMFT, a member of the Cape Cod Symposium 2024 (CCS) faculty, discusses the use of family genograms and motivational interviewing to identify and address intergenerational trauma and addiction within a family system.
Bruce Fischer, PhD, LP, LMFT, a...
09/07/2024
Psychiatry & Behavioral Health
Ken J. Martz, PsyD, MBA.
Q&As
Tapping Into Neuroplasticity to Power Addiction Recovery
09/06/2024
Kenneth J. Martz, PsyD, MBA, discusses how neuroplasticity can amplify traditional recovery techniques.
Kenneth J. Martz, PsyD, MBA, discusses how neuroplasticity can amplify traditional recovery techniques.
Kenneth J. Martz, PsyD, MBA,...
09/06/2024
Psychiatry & Behavioral Health
Lucia Cheng, MD
Q&As
How to Establish Better Virtual Patient Rapport
09/06/2024
Lucia Cheng, MD, offers clinical pearls for mental health clinicians practicing in a telehealth setting.
Lucia Cheng, MD, offers clinical pearls for mental health clinicians practicing in a telehealth setting.
Lucia Cheng, MD, offers clinical...
09/06/2024
Psych Congress Network

Videos

andrew penn
Videos
Decoding the FDA Committee's Decision to Reject MDMA-Assisted Therapy: Part 2
07/01/2024
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP,...
07/01/2024
Psych Congress Network
andrew penn
Videos
Decoding the FDA Committee's Decision to Reject MDMA-Assisted Therapy With Andrew Penn, MS, PMHNP
06/21/2024
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP,...
06/21/2024
Psych Congress Network
Samantha Lau
Videos
The Collaborative Care Approach and Future of Mental Health
02/14/2022
Samantha Lau, MSN, FNP-BC, PMHNP-BC, discusses the role of collaborative care in mental health as well as the future of mental health, especially relating to empowering patients to “know that their voices are supported.”
Samantha Lau, MSN, FNP-BC, PMHNP-BC, discusses the role of collaborative care in mental health as well as the future of mental health, especially relating to empowering patients to “know that their voices are supported.”
Samantha Lau, MSN, FNP-BC,...
02/14/2022
Psych Congress Network
Samantha Lau
Videos
Unpacking Women’s Mental Health Care and Trauma-Informed Psychotherapy
02/01/2022
Samantha Lau, MSN, FNP-BC, PMHNP-BC, discusses trauma-informed psychotherapy and how it “impacts someone's mental health, physical health, and relationships.”
Samantha Lau, MSN, FNP-BC, PMHNP-BC, discusses trauma-informed psychotherapy and how it “impacts someone's mental health, physical health, and relationships.”
Samantha Lau, MSN, FNP-BC,...
02/01/2022
Psych Congress Network
Craig Bryan, PsyD, ABPP
Videos
Creating a Crisis Response Plan for Patients With Suicidal Ideation and Trauma-Related Disorders
01/12/2022
Craig Bryan, PsyD, ABPP discusses creating a tailored crisis response plan that helps patients feel more in control of their mental health as well as building a positive clinician-patient relationship.
Craig Bryan, PsyD, ABPP discusses creating a tailored crisis response plan that helps patients feel more in control of their mental health as well as building a positive clinician-patient relationship.
Craig Bryan, PsyD, ABPP...
01/12/2022
Psych Congress Network
Craig Bryan, PsyD, ABPP
Videos
PTSD Comorbid Conditions and Suicidal Ideation Interventions
01/06/2022
Craig Bryan, PsyD, ABPP, explores clinical signs that help diagnose a patient with post-traumatic stress disorder (PTSD), the common comorbid conditions, and suicidal indications.
Craig Bryan, PsyD, ABPP, explores clinical signs that help diagnose a patient with post-traumatic stress disorder (PTSD), the common comorbid conditions, and suicidal indications.
Craig Bryan, PsyD, ABPP,...
01/06/2022
Psych Congress Network
Dr. Robin Carhart-Harris on the Power of Psychedelics
Videos
Dr. Robin Carhart-Harris on the Power of Psychedelics
07/22/2020
Robin Carhart-Harris, PhD, head of the Centre of Psychedelic Research at Imperial College London in England, discusses the power of psychedelics.
Robin Carhart-Harris, PhD, head of the Centre of Psychedelic Research at Imperial College London in England, discusses the power of psychedelics.
Robin Carhart-Harris, PhD, head...
07/22/2020
Psych Congress Network
Videos
Robin Carhart-Harris, PhD, Discusses Psychedelics at Davos Forum
02/07/2019
Psychedelics researcher Robin Carhart-Harris, PhD, who delivered the opening session at Psych Congress 2018, spoke about the compounds at the World Economic Forum Annual Meeting in Davos, Switzerland.
Psychedelics researcher Robin Carhart-Harris, PhD, who delivered the opening session at Psych Congress 2018, spoke about the compounds at the World Economic Forum Annual Meeting in Davos, Switzerland.
Psychedelics researcher Robin...
02/07/2019
Psych Congress Network
Videos
Using Psychedelics in Psychotherapy
10/23/2016
Psych Congress Steering Committee members Andrew Penn, RN, MS, NP, CNS, APRN-BC, and Saundra Jain, MA, PsyD, LPC, discuss the latest research on the use of psychedelics with psychotherapy.
Psych Congress Steering Committee members Andrew Penn, RN, MS, NP, CNS, APRN-BC, and Saundra Jain, MA, PsyD, LPC, discuss the latest research on the use of psychedelics with psychotherapy.
Psych Congress Steering...
10/23/2016
Psych Congress Network
Brooke Kempf
Videos
Addressing Misconceptions About LAI Antipsychotics
01/06/2025
Kempf emphasizes the power of patient education, addressing myths, and involving families to ease the daily medication burden. 
Kempf emphasizes the power of patient education, addressing myths, and involving families to ease the daily medication burden. 
Kempf emphasizes the power of...
01/06/2025
Psych Congress Network
Desiree Matthews, PMHNP-BC, CEO
Videos
How to Navigate Insurance When Treating Tardive Dyskinesia
01/06/2025
In this video, Desiree Matthews, PMHNP-BC, discusses how to navigate insurance policies when treating tardive dyskinesia.
In this video, Desiree Matthews, PMHNP-BC, discusses how to navigate insurance policies when treating tardive dyskinesia.
In this video, Desiree Matthews,...
01/06/2025
Psych Congress Network
Desiree Matthews, PMHNP-BC, CEO
Videos
How to Navigate Insurance When Treating Tardive Dyskinesia
01/06/2025
In this video, Desiree Matthews, PMHNP-BC, discusses how to navigate insurance policies when treating tardive dyskinesia.
In this video, Desiree Matthews, PMHNP-BC, discusses how to navigate insurance policies when treating tardive dyskinesia.
In this video, Desiree Matthews,...
01/06/2025
Psych Congress Network
Andrew Penn, PMHNP-BC
Videos
Best Practices for Deprescribing in Schizophrenia
12/05/2024
In this video, Andrew Penn, PMHNP-BC, NP, CNS, MS, RN offers some key clinical takeaways from his session on deprescribing and how it even has a place when treating patients living with serious mental illness like schizophrenia.
In this video, Andrew Penn, PMHNP-BC, NP, CNS, MS, RN offers some key clinical takeaways from his session on deprescribing and how it even has a place when treating patients living with serious mental illness like schizophrenia.
In this video, Andrew Penn,...
12/05/2024
Psych Congress Network
Rebecca Barbee, MSPAS, PA-C, CAQ-Psych
Videos
Understanding Antipsychotic-Induced Movement Disorders
12/05/2024
Rebecca Barbee, MSPAS, PA-C, CAQ-Psych, explains the differences between dystonia, akathisia, drug-induced Parkinsonism, and tardive dyskinesia, as well as the different management approaches for each.
Rebecca Barbee, MSPAS, PA-C, CAQ-Psych, explains the differences between dystonia, akathisia, drug-induced Parkinsonism, and tardive dyskinesia, as well as the different management approaches for each.
Rebecca Barbee, MSPAS, PA-C,...
12/05/2024
Psych Congress Network
Edward Kaftarian, MD.
Videos
How to Maintain Up-To-Date Telehealth Regulation Compliance
12/03/2024
Edward Kaftarian, MD, offers some practical tips for maintaining regulatory compliance while managing a busy telehealth practice.
Edward Kaftarian, MD, offers some practical tips for maintaining regulatory compliance while managing a busy telehealth practice.
Edward Kaftarian, MD, offers...
12/03/2024
Psych Congress Network
Dr Craig Chepke
Schizophrenia Conference Insights
Muscarinic Acetylcholine Receptors in Schizophrenia: A Shift From Dopamine D2 to Muscarinic Agonists
11/27/2024
In this video, Craig Chepke, MD, DFAPA, scientific director, Psych Congress, explains the vital differences between dopamine D2 receptor antipsychotics and muscarinic agonists for the treatment of schizophrenia, including mechanisms of action...
In this video, Craig Chepke, MD, DFAPA, scientific director, Psych Congress, explains the vital differences between dopamine D2 receptor antipsychotics and muscarinic agonists for the treatment of schizophrenia, including mechanisms of action...
In this video, Craig Chepke, MD,...
11/27/2024
Psych Congress Network
Edward Kaftarian, MD.
Videos
Major Changes to Telehealth Regulations May Be on the Horizon
11/25/2024
Edward Kaftarian, MD, explains possible upcoming changes to telehealth policy and practice.
Edward Kaftarian, MD, explains possible upcoming changes to telehealth policy and practice.
Edward Kaftarian, MD, explains...
11/25/2024
Psych Congress Network
3 roundtable participants
Videos
Overview of Anticholinergic Medications
11/25/2024
This roundtable video featuring Desiree Matthews, Jonathan Meyer, and Leslie Citrome provides background on the use of anticholinergic medications in psychiatry.
This roundtable video featuring Desiree Matthews, Jonathan Meyer, and Leslie Citrome provides background on the use of anticholinergic medications in psychiatry.
This roundtable video featuring...
11/25/2024
Psych Congress Network
3 roundtable participants
Videos
The Anticholinergic Burden of Psychotherapeutics
11/25/2024
This roundtable video featuring Desiree Matthews, Jonathan Meyer, and Leslie Citrome discusses the patient burden of anticholinergic drugs.
This roundtable video featuring Desiree Matthews, Jonathan Meyer, and Leslie Citrome discusses the patient burden of anticholinergic drugs.
This roundtable video featuring...
11/25/2024
Psych Congress Network

News

fda building sign
News
FDA Rejection of MDMA-Assisted Therapy for PTSD Divides Psychedelic Stakeholders
08/16/2024
The US Food and Drug Administration (FDA) last week rejected the new drug application (NDA) from Lykos Therapeutics for midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD) in conjunction with...
The US Food and Drug Administration (FDA) last week rejected the new drug application (NDA) from Lykos Therapeutics for midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD) in conjunction with...
The US Food and Drug...
08/16/2024
Psych Congress Network
FDA Considers Supplemental NDA for Brexpiprazole Plus Sertraline for PTSD
News
FDA Considers Supplemental NDA for Brexpiprazole Plus Sertraline for PTSD
07/24/2024
The US Food and Drug Administration recently accepted a supplemental New Drug Application for brexpiprazole in combination with sertraline for the treatment of adults with PTSD, announced codevelopers Otsuka Pharmaceutical Co. Ltd. and H....
The US Food and Drug Administration recently accepted a supplemental New Drug Application for brexpiprazole in combination with sertraline for the treatment of adults with PTSD, announced codevelopers Otsuka Pharmaceutical Co. Ltd. and H....
The US Food and Drug...
07/24/2024
Psych Congress Network
Grief-Related Psychiatric Conditions Common Among Bereaved Adults
News
Grief-Related Psychiatric Conditions Common Among Bereaved Adults
07/16/2024
PTSD, MDD, and PGD appear highly prevalent and comorbid among bereaved US adults, particularly those who experienced a traumatic loss of a psychologically close other.
PTSD, MDD, and PGD appear highly prevalent and comorbid among bereaved US adults, particularly those who experienced a traumatic loss of a psychologically close other.
PTSD, MDD, and PGD appear highly...
07/16/2024
Psych Congress Network
FDA
News
FDA Advisory Committee Rejects First MDMA Treatment for PTSD
06/06/2024
FDA committee rejected an MDMA-based therapy for adult PTSD treatment due to concerns about its effectiveness and the reliability of the data, despite positive study results.
FDA committee rejected an MDMA-based therapy for adult PTSD treatment due to concerns about its effectiveness and the reliability of the data, despite positive study results.
FDA committee rejected an...
06/06/2024
Psych Congress Network
Traumatic Events May Affect Psychiatric Disorder Development, Moreso Than Familial Factors
News
Traumatic Events May Affect Psychiatric Disorder Development, Moreso Than Familial Factors
01/23/2024
Assault, bereavement, and injury were significantly associated with an increased risk of subsequent psychiatric disorders, independent of familial background, in a nationwide cohort study recently published in JAMA Psychiatry. 
Assault, bereavement, and injury were significantly associated with an increased risk of subsequent psychiatric disorders, independent of familial background, in a nationwide cohort study recently published in JAMA Psychiatry. 
Assault, bereavement, and injury...
01/23/2024
Psych Congress Network
News
CPT III Codes for Psychedelic-Assisted Therapies Take Effect
01/05/2024
The temporary codes, which went into effect this week, allow providers to seek coverage and reimbursement for delivery of psychedelic-assisted therapies, pending their approval by the FDA.
The temporary codes, which went into effect this week, allow providers to seek coverage and reimbursement for delivery of psychedelic-assisted therapies, pending their approval by the FDA.
The temporary codes, which went...
01/05/2024
Psych Congress Network
News
MAPS PBC Submits New Drug Application for MDMA-Assisted Therapy for PTSD
12/12/2023
MAPS Public Benefit Corporation’s new drug application to the US Food and Drug Administration for the use of MDMA in combination with psychotherapy to treat post-traumatic stress disorder is the first filing to the FDA for any...
MAPS Public Benefit Corporation’s new drug application to the US Food and Drug Administration for the use of MDMA in combination with psychotherapy to treat post-traumatic stress disorder is the first filing to the FDA for any...
MAPS Public Benefit...
12/12/2023
Psych Congress Network
Andrew Penn, RN, PMHNP, and Charles Raison, MD
News
Studies Illustrate Potential of MDMA-, Psilocybin-Assisted Therapies
10/30/2023
Andrew Penn, RN, PMHNP, and Charles Raison, MD, shared findings from late-stage trials for MDMA-assisted therapy to treat post-traumatic stress disorder and the use of psilocybin for treatment-resistant depression and major depressive...
Andrew Penn, RN, PMHNP, and Charles Raison, MD, shared findings from late-stage trials for MDMA-assisted therapy to treat post-traumatic stress disorder and the use of psilocybin for treatment-resistant depression and major depressive...
Andrew Penn, RN, PMHNP, and...
10/30/2023
Psych Congress Network
FDA headquarters
News
FDA Issues Warning Highlighting Risks of Ketamine for Psychiatric Disorder Treatment
10/27/2023
The FDA has recently addressed the growing interest in compounded ketamine products, including oral formulations, for the treatment of psychiatric disorders and warns clinicians considering their use.
The FDA has recently addressed the growing interest in compounded ketamine products, including oral formulations, for the treatment of psychiatric disorders and warns clinicians considering their use.
The FDA has recently addressed...
10/27/2023
Psych Congress Network
News
Second Phase 3 Study of MDMA-Assisted Therapy for PTSD Confirms Findings
09/25/2023
Findings from a second Phase 3 study of MDMA-assisted therapy for post-traumatic stress disorder conducted by MAPS Public Benefit Corporation keep the company on track to submit a new drug application in 2023.
Findings from a second Phase 3 study of MDMA-assisted therapy for post-traumatic stress disorder conducted by MAPS Public Benefit Corporation keep the company on track to submit a new drug application in 2023.
Findings from a second Phase 3...
09/25/2023
Psych Congress Network
A teddy bear against a blue background wearing a mask and stethoscope.
News
Prenatal Glucocorticoid Exposure Linked With Increased Mental Disorder Risk
01/17/2025
Prenatal exposure to glucocorticoids was associated with an increased risk of some mental disorders at age 15, according to a study published in JAMA Network Open.
Prenatal exposure to glucocorticoids was associated with an increased risk of some mental disorders at age 15, according to a study published in JAMA Network Open.
Prenatal exposure to...
01/17/2025
Psych Congress Network
A child sleeps in bed on her stomach with her mouth hanging open
News
Loudness of Snoring May Indicate Greater Hyperactivity in Children and Adolescents
01/16/2025
Loudness of snoring, regardless of hypoxic burden and obstructive sleep apnea syndrome severity (OSAS), may contribute to hyperactivity in pediatric patients, according to an observational prospective study published in Sleep Medicine.
Loudness of snoring, regardless of hypoxic burden and obstructive sleep apnea syndrome severity (OSAS), may contribute to hyperactivity in pediatric patients, according to an observational prospective study published in Sleep Medicine.
Loudness of snoring, regardless...
01/16/2025
Psych Congress Network
Is it Time for a ‘Reconceptualization’ of TRD? Some Think Yes
News
Is it Time for a ‘Reconceptualization’ of TRD? Some Think Yes
01/14/2025
Treatment-resistant depression (TRD) may be a more complex and multifaceted condition than previously thought, with authors of a recent study calling for a “unified definition and reconceptualization” of the illness. Their findings were...
Treatment-resistant depression (TRD) may be a more complex and multifaceted condition than previously thought, with authors of a recent study calling for a “unified definition and reconceptualization” of the illness. Their findings were...
Treatment-resistant depression...
01/14/2025
Psych Congress Network
Veterans’ OUD Diagnoses Increased From 2005 to 2017, Then Declined
News
Veterans’ OUD Diagnoses Increased From 2005 to 2017, Then Declined
01/14/2025
The prevalence of OUD diagnoses increased from 2005 to 2017, peaked in 2017, and then declined until 2022, according to a recent cross-sectional study of national Veterans Health Administration (VHA) electronic health record data published in...
The prevalence of OUD diagnoses increased from 2005 to 2017, peaked in 2017, and then declined until 2022, according to a recent cross-sectional study of national Veterans Health Administration (VHA) electronic health record data published in...
The prevalence of OUD diagnoses...
01/14/2025
Psych Congress Network
News
Meta-Analysis Finds Little Support for Neurofeedback for ADHD
01/13/2025
Neurofeedback did not show meaningful clinical or neuropsychological benefit for individuals with attention-deficit/hyperactivity disorder (ADHD), according to results from a systematic review and meta-analysis published print in JAMA...
Neurofeedback did not show meaningful clinical or neuropsychological benefit for individuals with attention-deficit/hyperactivity disorder (ADHD), according to results from a systematic review and meta-analysis published print in JAMA...
Neurofeedback did not show...
01/13/2025
Psych Congress Network
US FDA sign
News
Posdinemab Granted Fast Track Designation by the FDA for Early Alzheimer Disease
01/10/2025
Posdinemab, a phosphorylated tau-directed monoclonal antibody (mAb) being studied for the treatment of early Alzheimer disease (AD), was granted Fast Track designation by the US Food and Drug Administration (FDA).
Posdinemab, a phosphorylated tau-directed monoclonal antibody (mAb) being studied for the treatment of early Alzheimer disease (AD), was granted Fast Track designation by the US Food and Drug Administration (FDA).
Posdinemab, a phosphorylated...
01/10/2025
Psych Congress Network
Minority of Patients With OUD Develop PW After Buprenorphine Initiation
News
Minority of Patients With OUD Develop PW After Buprenorphine Initiation
01/08/2025
A small group of patients with OUD developed buprenorphine-precipitated withdrawal (PW) in emergency department or hospital settings, according to recent retrospective cohort study results published in JAMA Network Open.
A small group of patients with OUD developed buprenorphine-precipitated withdrawal (PW) in emergency department or hospital settings, according to recent retrospective cohort study results published in JAMA Network Open.
A small group of patients with...
01/08/2025
Psych Congress Network
Methylphenidate or Atomoxetine Maintenance Safe During Pregnancy
News
Methylphenidate or Atomoxetine Maintenance Safe During Pregnancy
01/08/2025
Maintenance of methylphenidate or atomoxetine may be safe during pregnancy, according to recent systematic review and meta-analysis results published in JAMA Network Open. 
Maintenance of methylphenidate or atomoxetine may be safe during pregnancy, according to recent systematic review and meta-analysis results published in JAMA Network Open. 
Maintenance of methylphenidate...
01/08/2025
Psych Congress Network
brain waves schizophrenia transcranial magnetic stimulation
News
Review Questions Utility of tDCS for Cognitive Symptoms in Schizophrenia
01/08/2025
A recent meta-analysis questions the effectiveness of transcranial direct current stimulation (tDCS) for improving cognitive impairments in individuals with schizophrenia after finding no statistically significant difference in cognitive...
A recent meta-analysis questions the effectiveness of transcranial direct current stimulation (tDCS) for improving cognitive impairments in individuals with schizophrenia after finding no statistically significant difference in cognitive...
A recent meta-analysis questions...
01/08/2025
Psych Congress Network
Major Depressive Disorder MDD
News
Hypomanic Symptoms in Major Depression Linked With Treatment Resistance
01/03/2025
Common in patients with unipolar depression, hypomanic symptoms are associated with both treatment-resistant depression and reduced remission of suicidal thoughts, according to a study in the Journal of Affective Disorders.
Common in patients with unipolar depression, hypomanic symptoms are associated with both treatment-resistant depression and reduced remission of suicidal thoughts, according to a study in the Journal of Affective Disorders.
Common in patients with unipolar...
01/03/2025
Psych Congress Network

Quizzes

quiz
Quiz
Repeated Ketamine Infusion Shows Improvement for Which Disease State?
06/08/2022
Repeated ketamine infusions over 2 weeks were associated with large-magnitude improvement in what disease state, according to a recent study published in The American Journal of Psychiatry? Take the quiz to find out!
Repeated ketamine infusions over 2 weeks were associated with large-magnitude improvement in what disease state, according to a recent study published in The American Journal of Psychiatry? Take the quiz to find out!
Repeated ketamine infusions over...
06/08/2022
Psych Congress Network
Quiz
Quiz: PTSD Found to Be Associated With Symptoms of Which Disorder?
01/13/2020
A recent study found subthreshold and threshold post-traumatic stress disorder to be associated with symptoms of which disorder?
A recent study found subthreshold and threshold post-traumatic stress disorder to be associated with symptoms of which disorder?
A recent study found...
01/13/2020
Psych Congress Network
Quiz
Quiz
What percentage of people experience hypomanic symptoms during an MDD episode?
01/15/2025
According to a recent study published in the Journal of Affective Disorders, what percentage of people experienced hypomanic symptoms during a major depressive disorder (MDD) episode?
According to a recent study published in the Journal of Affective Disorders, what percentage of people experienced hypomanic symptoms during a major depressive disorder (MDD) episode?
According to a recent study...
01/15/2025
Psych Congress Network
Which U.S. region saw the most fentanyl pill seizures in 2023?
Quiz
Which US region saw the most fentanyl pill seizures in 2023?
01/15/2025
Do you remember the details of this study?
Do you remember the details of this study?
Do you remember the details of...
01/15/2025
Psych Congress Network
An illustration of a pencil marking answers on a quiz sheet.
Expert Insights Quiz
Resources for Telehealth Rules and Regulations
01/06/2025
Test your knowledge with this quiz!
Test your knowledge with this quiz!
Test your knowledge with this...
01/06/2025
Psych Congress Network
How long does worry need to be present in order to diagnose GAD?
Quiz
How long does worry need to be present in order to diagnose GAD?
01/03/2025
Test your diagnostic knowledge!
Test your diagnostic knowledge!
Test your diagnostic knowledge!
01/03/2025
Psych Congress Network
Pop quiz written on a blackboard with white chalk
Quiz
Antidepressant Discontinuation Symptoms
12/23/2024
Test your knowledge with this quick quiz!
Test your knowledge with this quick quiz!
Test your knowledge with this...
12/23/2024
Psych Congress Network
Four people ponder with question marks over their heads
Quiz
Prodromal Symptoms in Schizophrenia
12/18/2024
Test your knowledge with this quick quiz!
Test your knowledge with this quick quiz!
Test your knowledge with this...
12/18/2024
Psych Congress Network
Are men or women more affected by depressive episodes?
Quiz
Are men or women more affected by depressive episodes?
12/17/2024
Pop quiz!
Pop quiz!
Pop quiz!
12/17/2024
Psych Congress Network
After how many months is 'problematic' opioid use diagnosed as OUD?
Quiz
After how many months is 'problematic' opioid use diagnosed as OUD?
12/16/2024
Test your diagnostic knowledge!
Test your diagnostic knowledge!
Test your diagnostic knowledge!
12/16/2024
Psych Congress Network
DSM-5
Quiz
How does the DSM-5 define 'remission' in MDD?
12/13/2024
Quiz! What is the definition of remission in the context of major depressive disorder (MDD), according to the DSM-5-TR?
Quiz! What is the definition of remission in the context of major depressive disorder (MDD), according to the DSM-5-TR?
Quiz! What is the definition of...
12/13/2024
Psych Congress Network
DSM-5
Quiz
How does the chronicity of depressive symptoms affect MDD treatment and outcomes?
12/11/2024
12/11/2024
Psych Congress Network

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

Sign Up

Psych Congress Network Newsletter

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use